Moderna CEO highlights China's mRNA push

Moderna's CEO announced promising results from a Phase 3 melanoma trial combining its personalized mRNA cancer vaccine with Merck’s Keytruda, indicating progress in cancer treatment. The company emphasizes the importance of maintaining American manufacturing to protect U.S. healthcare and counter China's substantial government investment in biotechnology. Moderna has expanded its facilities in Massachusetts to ensure production remains on U.S. soil amid geopolitical and supply chain concerns.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل